BCAL Diagnostics Limited (ASX:BDX)
Australia · Delayed Price · Currency is AUD 0.1150
0.00 (0.00%)
Feb 4, 2026, 3:46 PM AEST
BCAL Diagnostics Company Description
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer.
It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening.
The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
BCAL Diagnostics Limited
| Country | Australia |
| Founded | 2010 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| CEO | Shane Ryan |
Contact Details
Address: 50 Clarence Street Sydney, NSW 2000 Australia | |
| Phone | 61 2 9078 7671 |
| Website | bcaldiagnostics.com |
Stock Details
| Ticker Symbol | BDX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000160921 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Shane Ryan M.B.A. | Chief Executive Officer |
| Jayne Andrea Shaw | Co-Founder and Executive Chairman |
| Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD | Chief Financial Officer and Company Secretary |
| Sean Alexander Kennedy | Director of Corporate Finance |
| Alexandra Feetham | Head of Innovation |
| Dr. Christopher Baldwin Ph.D. | Chief Commercial Officer |